2-Methyl-5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-imine, an edaravone analog, exerts neuroprotective effects against acute ischemic injury via inhibiting oxidative stress

Abstract

Oxidative stress plays an indispensable role in the pathogenesis of cerebral ischemia. Inhibiting oxidative stress has been considered as an effective approach for stroke treatment. Edaravone, a free radical scavenger, has been shown to prevent cerebral ischemic injury. However, the clinical efficacy of edaravone is limited because it has a low scavenging activity for superoxide anions (O₂^·−). Here, we report that 2-methyl-5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-imine, a novel small-molecule compound structurally related to edaravone, showed a stronger inhibitory effect on oxidative stress in vitro. In vivo, 2-methyl-5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-imine reversed transient middle cerebral artery occlusion-induced dysfunctions of superoxide dismutases and malondialdehyde, two proteins crucial for oxidative stress, suggesting a strengthened antioxidant system. Moreover, 2-methyl-5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-imine decreased blood brain barrier permeability. Then, we found that 2-methyl-5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-imine had a stronger neuroprotective effect than edaravone. More importantly, 2-methyl-5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-imine decreased not only infarct size and neurological deficits in the acute phase but also modified neurological severity score and escape latency in Morris water maze task in the delayed period, indicating enhanced neuroprotection, sensorimotor function and spatial memory. Together, these findings suggest that 2-methyl-5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-imine could be a preferable option for stroke treatment.

Keywords

neuroprotection / oxidative stress / scavenging activity / sensorimotor function / spatial memory / stroke

References

[1] Demaerschalk BM, Hwang HM, Leung G. US cost burden of ischemic stroke: a systematic literature review[J]. Am J Manag Care, 2010, 16(7): 525–533

[2] Chapman SN, Mehndiratta P, Johansen MC, Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke[J]. Vasc Health Risk Manag, 2014, 10: 75–87

[3] ]Moretti A, Ferrari F, Villa RF. Neuroprotection for ischaemic stroke: current status and challenges[J]. Pharmacol Ther, 2015, 146: 23–34

[4] Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies[J]. Expert Opin Emerg Drugs, 2007, 12(1): 97–112

[5] Dröge W. Free radicals in the physiological control of cell function[J]. Physiol Rev, 2002, 82(1): 47–95

[6] Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury[J]. Cell Mol Neurobiol, 1998, 18(6): 667–682

[7] Lo EH, Moskowitz MA, Jacobs TP. Exciting, radical, suicidal: how brain cells die after stroke[J]. Stroke, 2005, 36(2): 189–192

[8] Miyamoto N, Maki T, Pham LD, Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice[J]. Stroke, 2013, 44(12): 3516–3521

[9] Chen H, Yoshioka H, Kim GS, Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection[J]. Antioxid Redox Signal, 2011, 14(8): 1505–1517

[10] Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities[J]. Antioxid Redox Signal, 2010, 12(1): 125–169

[11] Abramov AY, Scorziello A, Duchen MR. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation[J]. J Neurosci, 2007, 27(5): 1129–1138

[12] Brennan AM, Suh SW, Won SJ, NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation[J]. Nat Neurosci, 2009, 12(7): 857–863

[13] Girouard H, Wang G, Gallo EF, NMDA receptor activation increases free radical production through nitric oxide and NOX2[J]. J Neurosci, 2009, 29(8): 2545–2552

[14] Kunz A, Anrather J, Zhou P, Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species[J]. J Cereb Blood Flow Metab, 2007, 27(3): 545–551

[15] Kahles T, Brandes RP. Which NADPH oxidase isoform is relevant for ischemic stroke? The case for nox 2[J]. Antioxid Redox Signal, 2013, 18(12): 1400–1417

[16] Han Z, Gao LY, Lin YH, Neuroprotection of taurine against reactive oxygen species is associated with inhibiting NADPH oxidases[J]. Eur J Pharmacol, 2016, 777: 129–135

[17] Yoshida H, Yanai H, Namiki Y, Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury[J]. CNS Drug Rev, 2006, 12(1): 9–20

[18] Yagi K, Kitazato KT, Uno M, Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator[J]. Stroke, 2009, 40(2): 626–631

[19] Wu HY, Tang Y, Gao LY, The synergetic effect of edaravone and borneol in the rat model of ischemic stroke[J]. Eur J Pharmacol, 2014, 740: 522–531

[20] Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy[J]? Expert Opin Pharmacother, 2010, 11(10): 1753–1763

[21] Banno M, Mizuno T, Kato H, The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia[J]. Neuropharmacology, 2005, 48(2): 283–290

[22] Zhang N, Komine-Kobayashi M, Tanaka R, Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain[J]. Stroke, 2005, 36(10): 2220–2225

[23] Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters[J]. Cerebrovasc Dis, 2003, 15(3): 222–229

[24] Zhou L, Li F, Xu HB, Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95[J]. Nat Med, 2010, 16(12): 1439–1443

[25] Zhou HH, Tang Y, Zhang XY, Delayed administration of Tat-HA-NR2B9c promotes recovery after stroke in rats[J]. Stroke, 2015, 46(5): 1352–1358

[26] Chen J, Li Y, Wang L, Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats[J]. Stroke, 2001, 32(4): 1005–1011

[27] Chen H, Song YS, Chan PH. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion[J]. J Cereb Blood Flow Metab, 2009, 29(7): 1262–1272

[28] Doeppner TR, Pehlke JR, Kaltwasser B, The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration[J]. J Cereb Blood Flow Metab, 2015, 35(12): 2089–2097

[29] Cheng T, Petraglia AL, Li Z, Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage[J]. Nat Med, 2006, 12(11): 1278–1285

[30] George PM, Steinberg GK. Novel stroke therapeutics: unraveling stroke pathophysiology and its impact on clinical treatments [J]. Neuron, 2015, 87(2): 297–309

[31] Kurian P, Obisesan TO, Craddock TJA. Oxidative species-induced excitonic transport in tubulin aromatic networks: Potential implications for neurodegenerative disease[J]. J Photochem Photobiol B, 2017, 175: 109–124

[32] Liu S, Liu M, Peterson S, Hydroxyl radical formation is greater in striatal core than in penumbra in a rat model of ischemic stroke[J]. J Neurosci Res, 2003, 71(6): 882–888

[33] Kern R, Nagayama M, Toyoda K, Comparison of the European and Japanese guidelines for the management of ischemic stroke[J]. Cerebrovasc Dis, 2013, 35(5): 402–418

[34] Wada T, Yasunaga H, Inokuchi R, Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator[J]. J Neurol Sci, 2014, 345(1–2): 106–111

[35] Amaro S, Chamorro Á. Translational stroke research of the combination of thrombolysis and antioxidant therapy[J]. Stroke, 2011, 42(5): 1495–1499

Acknowledgments

This work was supported by grants from National Natural Science Foundation of China (31530091, 91232304), National Key Research and Development Program of China (2016YFC1306703) and Natural Science Foundation of Jiangsu Province (BK20140905), and by the Collaborative Innovation Center for Cardiovascular Disease Translational Medicine. We thank Nanjing Zhongrui Pharmaceutical Co., Ltd. for the technical assistance.

RIGHTS & PERMISSIONS

2018 2018 by the Journal of Biomedical Research.